peegeltaoline

Peegeltaoline is a synthetic opioid analgesic developed by the pharmaceutical company Pfizer. It is a mu-opioid receptor agonist, meaning it binds to and activates the mu-opioid receptors in the brain, which are responsible for the analgesic (pain-relieving) effects of opioids. Peegeltaoline was initially developed as a potential treatment for chronic pain, but its development was discontinued in 2015 due to safety concerns. The drug was found to have a high potential for abuse and to cause respiratory depression, which can be life-threatening. Despite these concerns, peegeltaoline has been studied for its potential use in the treatment of other conditions, such as cancer pain and opioid-induced hyperalgesia. However, its use remains controversial due to its high abuse liability and the associated risks.